News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Features PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data Michael O'Riordan January 25, 2016